Skip to main content
OpenTrials

Clinical trial condition

Recurrent Ovarian Carcinoma

Explore clinical trials studying Recurrent Ovarian Carcinoma. Study availability and eligibility vary by location and protocol.

111 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Ovarian Carcinoma trial results

Completed

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00066456

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +19 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
View Trial Details
Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01294293

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +31 more
Locations
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1411 locations
View Trial Details
Active, Not Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 296 locations
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Conditions
Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, +64 more
Locations
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
View Trial Details

Related conditions